PT980205E - Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos - Google Patents
Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignosInfo
- Publication number
- PT980205E PT980205E PT98920098T PT98920098T PT980205E PT 980205 E PT980205 E PT 980205E PT 98920098 T PT98920098 T PT 98920098T PT 98920098 T PT98920098 T PT 98920098T PT 980205 E PT980205 E PT 980205E
- Authority
- PT
- Portugal
- Prior art keywords
- cisplatine
- adriamycin
- tall
- combination
- cells
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 title 2
- 229940009456 adriamycin Drugs 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002659 cell therapy Methods 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/51—Stomach
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/847,000 US6022538A (en) | 1995-06-06 | 1997-05-01 | Method of treating malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
PT980205E true PT980205E (pt) | 2003-11-28 |
Family
ID=25299529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT98920098T PT980205E (pt) | 1997-05-01 | 1998-04-30 | Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos |
Country Status (11)
Country | Link |
---|---|
US (1) | US6022538A (pt) |
EP (1) | EP0980205B1 (pt) |
JP (1) | JP4371437B2 (pt) |
AT (1) | ATE243522T1 (pt) |
AU (1) | AU734046B2 (pt) |
CA (1) | CA2288059C (pt) |
DE (1) | DE69815840T2 (pt) |
DK (1) | DK0980205T3 (pt) |
ES (1) | ES2202847T3 (pt) |
PT (1) | PT980205E (pt) |
WO (1) | WO1998048630A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001522226A (ja) * | 1997-01-31 | 2001-11-13 | リサーチ コーポレイション テクノロジーズ インコーポレイテッド | セミ−同種異系細胞での癌の免疫療法 |
ES2263205T3 (es) * | 1997-04-30 | 2006-12-01 | Hans Klingemann | Estirpes celulares citoliticas naturales y metodos de uso. |
US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
US6157376A (en) * | 1998-09-30 | 2000-12-05 | Genesis Microchip, Corp. | Method and apparatus for generating a target clock signal having a frequency of X/Y times the frequency of a reference clock signal |
US6828147B1 (en) | 1999-02-24 | 2004-12-07 | The Wistar Institute Of Anatomy And Biology | Method of modifying cytotoxic cells and uses thereof |
DE10112851C1 (de) | 2001-03-16 | 2002-10-10 | Gsf Forschungszentrum Umwelt | Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen |
DE10132502A1 (de) | 2001-07-05 | 2003-01-23 | Gsf Forschungszentrum Umwelt | Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen |
US20040115173A1 (en) * | 2002-02-15 | 2004-06-17 | Daniela Santoli | Method of treating inflammation, particularly diabetes |
WO2006050270A2 (en) * | 2004-11-02 | 2006-05-11 | The Government Of The United States Of America As Represented By The Secretary Department Of Health & Human Services | Compositions and methods for treating hyperproliferative disorders |
US20090214494A1 (en) * | 2005-03-29 | 2009-08-27 | The Board Of Trustees Of The University Of Illinoi | Cancer Vaccines and Therapeutic Methods |
CN110179976A (zh) * | 2019-05-22 | 2019-08-30 | 华中科技大学同济医学院附属同济医院 | 用于治疗癌症的组合药物制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166059A (en) * | 1987-06-16 | 1992-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy using gene fusions for genetic or acquired disorders |
US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5272082A (en) * | 1992-03-30 | 1993-12-21 | The Wistar Institute Of Anatomy & Biology | Cytotoxic T-ALL cell lines and uses therefor |
JP3541950B2 (ja) * | 1993-05-14 | 2004-07-14 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 癌およびウイルス性疾患を治療するための改変化tall−104細胞の使用 |
-
1997
- 1997-05-01 US US08/847,000 patent/US6022538A/en not_active Expired - Lifetime
-
1998
- 1998-04-30 PT PT98920098T patent/PT980205E/pt unknown
- 1998-04-30 WO PCT/US1998/008835 patent/WO1998048630A1/en active IP Right Grant
- 1998-04-30 DE DE69815840T patent/DE69815840T2/de not_active Expired - Lifetime
- 1998-04-30 DK DK98920098T patent/DK0980205T3/da active
- 1998-04-30 EP EP98920098A patent/EP0980205B1/en not_active Expired - Lifetime
- 1998-04-30 JP JP54743098A patent/JP4371437B2/ja not_active Expired - Lifetime
- 1998-04-30 ES ES98920098T patent/ES2202847T3/es not_active Expired - Lifetime
- 1998-04-30 AU AU72744/98A patent/AU734046B2/en not_active Expired
- 1998-04-30 AT AT98920098T patent/ATE243522T1/de active
- 1998-04-30 CA CA2288059A patent/CA2288059C/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2002512618A (ja) | 2002-04-23 |
WO1998048630A1 (en) | 1998-11-05 |
ATE243522T1 (de) | 2003-07-15 |
DE69815840T2 (de) | 2004-05-06 |
AU7274498A (en) | 1998-11-24 |
EP0980205A1 (en) | 2000-02-23 |
DK0980205T3 (da) | 2003-10-20 |
EP0980205A4 (en) | 2001-11-07 |
DE69815840D1 (de) | 2003-07-31 |
AU734046B2 (en) | 2001-05-31 |
ES2202847T3 (es) | 2004-04-01 |
US6022538A (en) | 2000-02-08 |
CA2288059C (en) | 2010-07-06 |
CA2288059A1 (en) | 1998-11-05 |
EP0980205B1 (en) | 2003-06-25 |
JP4371437B2 (ja) | 2009-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2301032A1 (en) | A method of preventing or treating estrogen-dependent diseases and disorders | |
IL138979A0 (en) | Use of cannabinoids as anti-inflammatory agents | |
NO983429L (no) | Anvendelse av et texaphyrin til fremstilling av et medikament for anvendelse med et kjemoterapeutisk middel i kreftkjemosensitivisering | |
DE69936444D1 (de) | Systemische verabreichung von serum-stabilen plasmid-lipid partikeln zur krebstherapie | |
PT980205E (pt) | Utilizacao da combinacao de celulas tall-104 com adriamicina ou cisplatina na terapia de tumores malignos | |
BG106057A (en) | Method of enhancing the efficacy of anti-tumour agents | |
NZ507570A (en) | Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate | |
TR199800244T2 (xx) | Griseofulvinin, kanserlerin ilerlemesini �nlemede kullan�m�. | |
AU6178198A (en) | Method of treating a tumor | |
WO2001006990A3 (en) | Use of etodolac to treat cancer | |
PT1085884E (pt) | Combinacao de compostos seleniferos com gemcitabina ou mitomicina c | |
IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
MX9606559A (es) | Terapia para el cancer usando linfotoxina. | |
WO2001034131A3 (en) | Combination chemotherapy | |
ZA986720B (en) | Photoresponsive sunscreen compositions | |
MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
ATE232398T1 (de) | Verwendung von einer pharmazeutischen zusammensetzung enthaltende ein antikrebs mittel und mindestens ein peptid | |
IL131478A0 (en) | Methods for treatment of scar tissue | |
MD1569G2 (ro) | Metodă de tratament al cancerului mamar în perioada preoperatorie | |
MD798G2 (ro) | Metoda de tratament a cancerului mamar | |
AU3274597A (en) | Remedies and preventives for stomatitis | |
ES2012547A6 (es) | Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas. | |
TR200000728T2 (tr) | Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı. | |
NZ506005A (en) | Recombinant proteins derived from hgf and msp | |
AU6514299A (en) | Methods for the treatment of cancer using cytokines in combination with low level doses of chemotherapy and/or radiotherapy |